{ "company": "Natera", "ticker": "NTRA", "period": { "from": "2026-03-01", "to": "2026-03-31", "days": 30 }, "sentiment_breakdown": { "positive": 46, "negative": 32, "neutral": 32 }, "synthesis": { "executive_summary": "**Executive Summary: Natera (NTRA) Sentiment Analysis - March 2026**\n\nNatera (NTRA) experienced a moderately positive sentiment trend during March 2026, with 46 (41.8%) positive items, 32 (29.1%) negative items, and 32 (29.1%) neutral items out of a total of 110 analyzed. Key drivers for positive sentiment included robust growth projections for the Cell-Free DNA (cfDNA) testing market, expected to reach USD 39.43 billion by 2035, and increased institutional investment in NTRA shares. Conversely, negative sentiment was primarily influenced by broader concerns within the oncology sector, including calls for increased colorectal cancer research funding and challenges in advanced cancer treatment studies.\n\nSignificant positive events included the optimistic forecast for the Cell-Free DNA testing market, which directly benefits Natera's strategic positioning, and substantial share acquisitions by institutional investors such as CIBC Private Wealth Group LLC, reflecting strong market confidence. On the negative front, a notable item concerning Natera's Signatera assay, which detailed its clinical utility in identifying relapse risk for anal and rectal cancers, was assigned a negative sentiment. While the content highlighted the assay's utility, the negative classification suggests market sensitivity to cancer-related news or the implications of relapse identification.", "key_findings": [ "✓ Long-term efficacy and safety of pegunigalsidase alfa administered every 4 weeks in adults with Fabry disease: results from up to 5 years of the BRIGHT F51 phase III, open-label extension study.", "✓ Cell-Free DNA (cfDNA) Testing Market Size to Reach USD 39.43 Billion by 2035; Growth is Propelling Owing to Continuous Growth of Genomics Research Globally | SNS Insider", "✓ Dakota Wealth Management Buys Shares of 5,921 Natera, Inc. $NTRA", "✗ Colorectal Cancer Advocates Urge Congress to Fund New Research", "✗ The combination of a cancer vaccine, pembrolizumab, and stereotactic body radiation in patients with locally advanced pancreatic cancer: a single-arm, phase II study.", "✗ Prevalence of High-Risk Human Papillomavirus and Associated Risk Factors Among Individuals With Head and Neck Cancer in a National Referral Center in Tanzania." ], "overall_sentiment": "mixed" }, "top_positive": [ { "title": "Long-term efficacy and safety of pegunigalsidase alfa administered every 4 weeks in adults with Fabry disease: results from up to 5 years of the BRIGHT F51 phase III, open-label extension study.", "date": "2026 Mar 2", "source": "pubmed", "score": 0.753 }, { "title": "Cell-Free DNA (cfDNA) Testing Market Size to Reach USD 39.43 Billion by 2035; Growth is Propelling Owing to Continuous Growth of Genomics Research Globally | SNS Insider", "date": "2026-03-10", "source": "news", "score": 0.66 }, { "title": "Dakota Wealth Management Buys Shares of 5,921 Natera, Inc. $NTRA", "date": "2026-03-29", "source": "alpha_vantage", "score": 0.66 }, { "title": "CIBC Private Wealth Group LLC Buys 53,086 Shares of Natera, Inc. $NTRA", "date": "2026-03-20", "source": "alpha_vantage", "score": 0.66 }, { "title": "Oncology Precision Medicine Market Trends and Investment Opportunities 2026-2030 - Advancements in CAR-T and Gene Therapies Propel Precision Oncology Growth", "date": "2026-03-27", "source": "news", "score": 0.637 }, { "title": "Signatera Oncology Test Drives Natera’s (NTRA) Growth", "date": "2026-03-04", "source": "news", "score": 0.637 }, { "title": "World Baseball Classic set to begin. What to know, odds, schedules", "date": "2026-03-05", "source": "news", "score": 0.599 }, { "title": "Natera (NASDAQ: NTRA) president awarded RSUs, sells shares for tax", "date": "2026-03-12", "source": "alpha_vantage", "score": 0.599 }, { "title": "Natera, Inc. $NTRA Shares Sold by Assenagon Asset Management S.A.", "date": "2026-03-28", "source": "alpha_vantage", "score": 0.572 }, { "title": "Natera (NTRA) co-founder reports RSU grant and small tax-driven share sale", "date": "2026-03-12", "source": "alpha_vantage", "score": 0.572 } ], "top_negative": [ { "title": "Colorectal Cancer Advocates Urge Congress to Fund New Research", "date": "2026-03-27", "source": "news", "score": -0.945 }, { "title": "The combination of a cancer vaccine, pembrolizumab, and stereotactic body radiation in patients with locally advanced pancreatic cancer: a single-arm, phase II study.", "date": "2026 Mar 1", "source": "pubmed", "score": -0.832 }, { "title": "Prevalence of High-Risk Human Papillomavirus and Associated Risk Factors Among Individuals With Head and Neck Cancer in a National Referral Center in Tanzania.", "date": "2026-03-31", "source": "pubmed", "score": -0.758 }, { "title": "Cancer DNA test ties anal and rectal tumors to relapse odds", "date": "2026-03-16", "source": "alpha_vantage", "score": -0.66 }, { "title": "ASO Author Reflections: New Insights for Personalized HIPEC Strategies in Colorectal Cancer Peritoneal Metastases.", "date": "2026 Mar 2", "source": "pubmed", "score": -0.66 }, { "title": "Cancer type-specific variation in patterns of driver alterations across 50,000 tumors.", "date": "2026 Mar 2", "source": "pubmed", "score": -0.66 }, { "title": "Proton therapy for oropharyngeal cancer: survival, toxicity, and functional outcomes.", "date": "2026 Mar 2", "source": "pubmed", "score": -0.66 }, { "title": "Senescence-directed nanotherapy ameliorates fibrosis and overcomes immune exclusion in cancer.", "date": "2026 Mar 4", "source": "pubmed", "score": -0.66 }, { "title": "Impact of pathologic response and individual prognosis after neoadjuvant treatment in patients with early HER2+ and triple-negative breast cancer.", "date": "2026 Mar 1", "source": "pubmed", "score": -0.66 }, { "title": "Use of ctDNA in Older Women with ER+ Breast Cancer to Facilitate Surgical De-escalation: A Prospective, Hybrid-Decentralized Trial with Correlative Studies.", "date": "2026 Mar 1", "source": "pubmed", "score": -0.66 } ], "raw_data": { "total_items": 110, "items": [ { "source": "news", "source_name": "GlobeNewswire", "title": "Colorectal Cancer Advocates Urge Congress to Fund New Research", "description": "With Young Lives at Stake, More Than 250 Colorectal Cancer Advocates Demand Action With Young Lives at Stake, More Than 250 Colorectal Cancer Advocates Demand Action", "url": "https://www.globenewswire.com/news-release/2026/03/27/3263970/0/en/Colorectal-Cancer-Advocates-Urge-Congress-to-Fund-New-Research.html", "date": "2026-03-27", "published_at": "2026-03-27T16:31:00Z", "sentiment": { "label": "negative", "score": -0.945, "confidence": 0.95 } }, { "source": "news", "source_name": "GlobeNewswire", "title": "Oncology Precision Medicine Market Trends and Investment Opportunities 2026-2030 - Advancements in CAR-T and Gene Therapies Propel Precision Oncology Growth", "description": "Dublin, March 27, 2026 (GLOBE NEWSWIRE) -- The \"Oncology Precision Medicine Market Report 2026\" has been added to ResearchAndMarkets.com's offering. ...", "url": "https://www.globenewswire.com/news-release/2026/03/27/3263857/28124/en/Oncology-Precision-Medicine-Market-Trends-and-Investment-Opportunities-2026-2030-Advancements-in-CAR-T-and-Gene-Therapies-Propel-Precision-Oncology-Growth.html", "date": "2026-03-27", "published_at": "2026-03-27T14:44:00Z", "sentiment": { "label": "positive", "score": 0.637, "confidence": 0.64 } }, { "source": "news", "source_name": "GlobeNewswire", "title": "IMDX Submits GraftAssureDx for FDA Review and Reports Q4 2025 Results", "description": "NASHVILLE, Tenn., March 26, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., iMDx, (Nasdaq: IMDX), today published the following letter to shareholders in conjunction with its fourth quarter results:", "url": "https://www.globenewswire.com/news-release/2026/03/26/3263407/0/en/IMDX-Submits-GraftAssureDx-for-FDA-Review-and-Reports-Q4-2025-Results.html", "date": "2026-03-26", "published_at": "2026-03-26T20:05:00Z", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "news", "source_name": "GlobeNewswire", "title": "Predictive Biomarkers Market to Reach USD 156.85 Billion by 2035; Rising Adoption of Precision Medicine and Targeted Therapies Driving Market Growth – SNS Insider", "description": "Rising Chronic Disease Burden, AI-Driven Biomarker Discovery, and Expanding Companion Diagnostics Pipelines Fuel Unprecedented Market Expansion. Rising Chronic Disease Burden, AI-Driven Biomarker Discovery, and Expanding Companion Diagnostics Pipelines Fuel U…", "url": "https://www.globenewswire.com/news-release/2026/03/17/3257053/0/en/Predictive-Biomarkers-Market-to-Reach-USD-156-85-Billion-by-2035-Rising-Adoption-of-Precision-Medicine-and-Targeted-Therapies-Driving-Market-Growth-SNS-Insider.html", "date": "2026-03-17", "published_at": "2026-03-17T11:45:00Z", "sentiment": { "label": "negative", "score": -0.477, "confidence": 0.48 } }, { "source": "news", "source_name": "GlobeNewswire", "title": "Cell-Free DNA (cfDNA) Testing Market Size to Reach USD 39.43 Billion by 2035; Growth is Propelling Owing to Continuous Growth of Genomics Research Globally | SNS Insider", "description": "Cell-Free DNA Testing Market to reach USD 39.43 Bn by 2035, driven by rising adoption of non-invasive prenatal screening, liquid biopsy....", "url": "https://www.globenewswire.com/news-release/2026/03/10/3252493/0/en/Cell-Free-DNA-cfDNA-Testing-Market-Size-to-Reach-USD-39-43-Billion-by-2035-Growth-is-Propelling-Owing-to-Continuous-Growth-of-Genomics-Research-Globally-SNS-Insider.html", "date": "2026-03-10", "published_at": "2026-03-10T09:00:00Z", "sentiment": { "label": "positive", "score": 0.66, "confidence": 0.66 } }, { "source": "news", "source_name": "El Paso Times", "title": "World Baseball Classic set to begin. What to know, odds, schedules", "description": "The World Baseball Classic is set to begin its two-week run to crown a champion. Schedules for Team USA and Mexico, odds, how to watch.", "url": "https://www.elpasotimes.com/story/sports/baseball/2026/03/05/world-baseball-classic-teams-usa-mexico-start-play-in-tournament/88984665007/", "date": "2026-03-05", "published_at": "2026-03-05T16:07:33Z", "sentiment": { "label": "positive", "score": 0.599, "confidence": 0.6 } }, { "source": "news", "source_name": "Thesportingtribune.com", "title": "Inside the 2026 World Baseball Classic: Pool-by-Pool Preview", "description": "MIAMI -- Three years ago at LoanDepot Park, Shohei Ohtani struck out then-Angels teammate Mike Trout for the final out in Japan's World Baseball Classic title.", "url": "https://www.thesportingtribune.com/2026/03/04/world-baseball-classic-preview", "date": "2026-03-04", "published_at": "2026-03-04T17:57:07Z", "sentiment": { "label": "negative", "score": -0.25, "confidence": 0.25 } }, { "source": "news", "source_name": "Yahoo Entertainment", "title": "Signatera Oncology Test Drives Natera’s (NTRA) Growth", "description": "Carillon Tower Advisers, an investment management company, released its fourth-quarter 2025 investor letter for the “Carillon Eagle Mid Cap Growth Fund”. A...", "url": "https://finance.yahoo.com/news/signatera-oncology-test-drives-natera-121023663.html", "date": "2026-03-04", "published_at": "2026-03-04T12:10:23Z", "sentiment": { "label": "positive", "score": 0.637, "confidence": 0.64 } }, { "source": "news", "source_name": "USA Today", "title": "Who's in WBC? Team by team look at MLB stars playing on global stage", "description": "The World Baseball Classic is back in 2026, with 20 teams participating for world bragging rights. Here's all the MLB players who are on rosters.", "url": "https://www.usatoday.com/story/sports/mlb/wbc/2026/03/03/mlb-players-in-wbc-2026/88876535007/", "date": "2026-03-03", "published_at": "2026-03-03T11:01:44Z", "sentiment": { "label": "positive", "score": 0.202, "confidence": 0.2 } }, { "source": "news", "source_name": "Marca", "title": "World Baseball Classic Rosters 2026: USA, Japan, Mexico and all participating countries", "description": "The 2026 World Baseball Classic is about to begin and its protagonists have already been defined. The national teams have announced their official rosters and the tournament promis", "url": "https://www.marca.com/en/mlb/2026/03/03/69a6bd46ca4741d3348b456d.html", "date": "2026-03-03", "published_at": "2026-03-03T10:59:12Z", "sentiment": { "label": "negative", "score": -0.2, "confidence": 0.2 } }, { "source": "alpha_vantage", "title": "Dakota Wealth Management Buys Shares of 5,921 Natera, Inc. $NTRA", "url": "https://www.marketbeat.com/instant-alerts/filing-dakota-wealth-management-buys-shares-of-5921-natera-inc-ntra-2026-03-29/", "date": "2026-03-29", "summary": "Dakota Wealth Management purchased 5,921 shares of Natera, Inc. (NASDAQ:NTRA), valued at approximately $1.36 million, in the fourth quarter, joining other institutional investors increasing their stake. Despite strong institutional ownership (99.90%), company insiders, including CEO Steven Leonard Chapman, have recently sold a significant number of shares. Natera exceeded Q4 earnings expectations with $0.35 EPS against an estimated -$0.46, and analysts maintain a \"Moderate Buy\" rating with an av", "sentiment_score": 0.28068, "sentiment_label": "Somewhat-Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.66, "confidence": 0.66 } }, { "source": "alpha_vantage", "title": "DAVENPORT & Co LLC Takes Position in Natera, Inc. $NTRA", "url": "https://www.marketbeat.com/instant-alerts/filing-davenport-co-llc-takes-position-in-natera-inc-ntra-2026-03-28/", "date": "2026-03-28", "summary": "DAVENPORT & Co LLC has initiated a new position in Natera, Inc. (NASDAQ: NTRA) during Q4, acquiring 14,032 shares valued at approximately $3.215 million. While institutional investors hold a significant portion of the stock, recent insider activity shows sales by CEO Steven Leonard Chapman and other insiders totaling over $74 million in the last 90 days. Natera recently beat quarterly earnings and revenue estimates and holds a \"Moderate Buy\" consensus rating from analysts with an average price t", "sentiment_score": 0.322952, "sentiment_label": "Somewhat-Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Natera, Inc. $NTRA Shares Sold by Assenagon Asset Management S.A.", "url": "https://www.marketbeat.com/instant-alerts/filing-natera-inc-ntra-shares-sold-by-assenagon-asset-management-sa-2026-03-28/", "date": "2026-03-28", "summary": "Assenagon Asset Management S.A. significantly reduced its stake in Natera, Inc. (NASDAQ:NTRA) by 85.5% in the fourth quarter, selling over 261,000 shares. Despite Natera reporting a surprise earnings beat with $0.35 EPS against a -$0.46 consensus, and revenue exceeding estimates, the company still has negative margins and analysts anticipate a negative EPS for the current year. Insider selling has also been observed, with major officers offloading shares, while institutional investors maintain a", "sentiment_score": -0.137961, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.572, "confidence": 0.57 } }, { "source": "alpha_vantage", "title": "A Look At Natera (NTRA) Valuation After Recent Share Price Weakness", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntra/natera/news/a-look-at-natera-ntra-valuation-after-recent-share-price-wea", "date": "2026-03-28", "summary": "Natera (NTRA) has experienced recent share price weakness, though its long-term shareholder returns remain strong. Despite the pullback, the company is considered undervalued by some intrinsic estimates and analyst price targets, with a fair value pegged at $260.65 per share due to growth in molecular diagnostics. However, its current P/S ratio is above the industry average, suggesting less room for error if growth falters.", "sentiment_score": 0.303779, "sentiment_label": "Somewhat-Bullish", "relevance_score": 1.0, "sentiment": { "label": "negative", "score": -0.153, "confidence": 0.15 } }, { "source": "alpha_vantage", "title": "Natera Inc (NTRA) Shares Down 4.14% on Mar 27", "url": "https://www.gurufocus.com/news/8750024/natera-inc-ntra-shares-down-414-on-mar-27", "date": "2026-03-28", "summary": "Shares of Natera Inc (NTRA) dropped 4.14% on March 27, reaching an intraday low of $187.86 before settling at $188.02. This stock price is 26.66% below its 52-week high and 49.96% above its 52-week low. Wall Street analysts have an average target price of $253.56 for NTRA, indicating an \"Outperform\" status and a potential upside of 34.86%.", "sentiment_score": -0.242046, "sentiment_label": "Somewhat-Bearish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "Elanco, Tandem Diabetes, Fortrea, Natera, and Myriad Genetics Shares Plummet, What You Need To Know", "url": "https://www.tradingview.com/news/stockstory:97d4478af094b:0-elanco-tandem-diabetes-fortrea-natera-and-myriad-genetics-shares-plummet-what-you-need-to-know/", "date": "2026-03-27", "summary": "Several stocks including Elanco, Tandem Diabetes, Fortrea, Natera, and Myriad Genetics experienced significant drops in the afternoon trading session. This market downturn is attributed to rising uncertainty from the U.S.-Iran conflict and policy deadlines set by the Trump administration, leading to a dip in consumer confidence. Despite the broader market reaction, the article highlights potential buying opportunities in these quality stocks given that markets often overreact to news.", "sentiment_score": -0.204809, "sentiment_label": "Somewhat-Bearish", "relevance_score": 0.920751, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "Vanguard disaggregates holdings; reports 0 shares for Natera (NTRA)", "url": "https://www.stocktitan.net/sec-filings/NTRA/schedule-13g-a-natera-inc-amended-passive-investment-disclosure-b9cf16bd8fd9.html", "date": "2026-03-27", "summary": "Vanguard has reported 0 beneficial shares owned in Natera (NTRA) following an internal realignment effective January 12, 2026. This change means that certain Vanguard subsidiaries will now report their holdings separately, although their investment strategies remain unchanged. The filing indicates that The Vanguard Group itself no longer holds beneficial ownership over securities held by these disaggregated subsidiaries.", "sentiment_score": 0.010491, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "Wealth Enhancement Advisory Services LLC Has $11.48 Million Stock Position in Natera, Inc. $NTRA", "url": "https://www.marketbeat.com/instant-alerts/filing-wealth-enhancement-advisory-services-llc-has-1148-million-stock-position-in-natera-inc-ntra-2026-03-27/", "date": "2026-03-27", "summary": "Wealth Enhancement Advisory Services LLC increased its stake in Natera, Inc. (NASDAQ:NTRA) by 25.9% to holdings worth $11.48 million, contributing to institutional investors owning 99.90% of the company. Natera surpassed Q4 earnings and revenue estimates but remains unprofitable with negative margins. Despite significant insider selling totaling $74.09 million in the last 90 days, analysts maintain a \"Moderate Buy\" rating with an average price target of $253.47.", "sentiment_score": 0.129752, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.494, "confidence": 0.49 } }, { "source": "alpha_vantage", "title": "Is It Time To Reassess Natera (NTRA) After Its Recent Share Price Pullback", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntra/natera/news/is-it-time-to-reassess-natera-ntra-after-its-recent-share-pr", "date": "2026-03-26", "summary": "This article examines Natera (NTRA) after a recent share price pullback, noting its strong 1-year and 3-year returns despite a current decline. Using two valuation methods, a Discounted Cash Flow (DCF) analysis suggests Natera is 37.8% undervalued, while a Price-to-Sales (P/S) ratio comparison indicates it might be overvalued relative to its Fair Ratio. The article encourages investors to use \"Narratives\" on the Simply Wall St platform to form their own valuation based on differing assumptions.", "sentiment_score": 0.297392, "sentiment_label": "Somewhat-Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "If You Invested $1000 In Natera Stock 10 Years Ago, You Would Have This Much Today", "url": "https://www.sahmcapital.com/news/content/if-you-invested-1000-in-natera-stock-10-years-ago-you-would-have-this-much-today-2026-03-25", "date": "2026-03-25", "summary": "Natera (NTRA) has significantly outperformed the market over the last decade, with an average annual return of 36.62%. An initial investment of $1000 in Natera stock 10 years ago would now be worth $22,576.05. This highlights the powerful effect of compounded returns on investment growth over time.", "sentiment_score": 0.494069, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Natera (NTRA) Launches Zenith Genomic Assay", "url": "https://www.insidermonkey.com/blog/natera-ntra-launches-zenith-genomic-assay-1723130/", "date": "2026-03-24", "summary": "Natera, Inc. (NASDAQ: NTRA) has commercially launched Zenith, a whole-genome sequencing assay designed to improve the diagnosis of rare genetic conditions and shorten the diagnostic journey for millions of Americans. This new clinical tool aims to address the significant unmet needs and economic burden associated with rare diseases. The launch follows a recent price target reduction for Natera by Morgan Stanley, though the firm maintained an Overweight rating.", "sentiment_score": 0.212992, "sentiment_label": "Somewhat-Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Natera, Inc. (NASDAQ:NTRA) Given Consensus Recommendation of \"Moderate Buy\" by Brokerages", "url": "https://www.marketbeat.com/instant-alerts/natera-inc-nasdaqntra-given-consensus-recommendation-of-moderate-buy-by-brokerages-2026-03-24/", "date": "2026-03-24", "summary": "Eighteen brokerages have given Natera, Inc. (NASDAQ:NTRA) a \"Moderate Buy\" consensus recommendation, with an average 12-month price target of $253.47. Despite beating Q4 earnings and revenue estimates, the company remains unprofitable with negative net margin and return on equity. Recent insider selling by the CFO and CEO has been noted, although institutional investors have increased their holdings.", "sentiment_score": 0.135373, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Natera Inc (NTRA) Stock Price Up 2.86% on Mar 23", "url": "https://www.gurufocus.com/news/8736353/natera-inc-ntra-stock-price-up-286-on-mar-23", "date": "2026-03-23", "summary": "Shares of Natera Inc (NTRA) rose by 2.86% in mid-day trading on March 23, closing at $200.87. Wall Street analysts forecast an average target price of $253.56, indicating an upside of 26.23%, with an \"Outperform\" recommendation. GuruFocus estimates a one-year GF Value of $213.32 for NTRA, suggesting a 6.2% upside.", "sentiment_score": 0.340711, "sentiment_label": "Somewhat-Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Natera (NASDAQ: NTRA) co-founder reports 4,570-share planned stock sale", "url": "https://www.stocktitan.net/sec-filings/NTRA/form-4-natera-inc-insider-trading-activity-fc5307cf2697.html", "date": "2026-03-21", "summary": "Natera's co-founder, Jonathan Sheena, reported planned sales of 4,570 shares of common stock on March 18 and March 20, 2026. The sales were executed at prices ranging from approximately $196 to $201 per share under pre-arranged Rule 10b5-1 trading plans adopted in June and December 2024. These transactions included both direct holdings and shares held by Caraluna 1 Trust and Caraluna 2 Trust, with Sheena disclaiming beneficial ownership of the trust-held shares.", "sentiment_score": -0.219599, "sentiment_label": "Somewhat-Bearish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Natera co-founder Jonathan Sheena sells shares worth $908,301", "url": "https://www.investing.com/news/insider-trading-news/natera-cofounder-jonathan-sheena-sells-shares-worth-908301-93CH-4574014", "date": "2026-03-21", "summary": "Natera co-founder Jonathan Sheena sold 5,360 shares of the company's common stock for a total of $908,301 across two transactions in March 2026. Despite a year-to-date decline, Natera's stock gained 4% in the week of the sales and analysts maintain a bullish outlook with price targets up to $300. The company's market capitalization stands at $27.81 billion, though InvestingPro analysis suggests the stock is currently overvalued.", "sentiment_score": 0.045667, "sentiment_label": "Neutral", "relevance_score": 0.301377, "sentiment": { "label": "positive", "score": 0.477, "confidence": 0.48 } }, { "source": "alpha_vantage", "title": "Jonathan Sheena reports multiple share sales for NTRA (NASDAQ: NTRA)", "url": "https://www.stocktitan.net/sec-filings/NTRA/144-natera-inc-sec-filing-9fbc92a076b5.html", "date": "2026-03-20", "summary": "Jonathan Sheena, an affiliate of Natera, Inc. (NASDAQ: NTRA), has reported multiple proposed sales of Common shares through a Form 144 filing. The filing details various transactions by Sheena, including sales of 2,981 shares for $699,755.00 on January 20, 2026, 3,070 shares for $614,710.00 on March 2, 2026, and 3,070 shares for $608,370.00 on March 18, 2026, handled by Charles Schwab & Co., Inc. These transactions are considered routine dispositions by an affiliate.", "sentiment_score": 0.028963, "sentiment_label": "Neutral", "relevance_score": 0.301366, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "Natera Inc (NTRA) Shares Gap Down to $196.73 on Mar 20", "url": "https://www.gurufocus.com/news/8731347/natera-inc-ntra-shares-gap-down-to-19673-on-mar-20", "date": "2026-03-20", "summary": "Shares of Natera Inc (NTRA) dropped by 2.96% to $196.73 on March 20, trading at 23.26% below its 52-week high and 56.91% above its 52-week low. Analysts forecast an average target price of $253.56, indicating a potential upside of 28.89%, with a consensus rating of \"Outperform.\" GuruFocus estimates the fair value (GF Value) at $213.41, suggesting an 8.48% upside.", "sentiment_score": -0.248637, "sentiment_label": "Somewhat-Bearish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "CIBC Private Wealth Group LLC Buys 53,086 Shares of Natera, Inc. $NTRA", "url": "https://www.marketbeat.com/instant-alerts/filing-cibc-private-wealth-group-llc-buys-53086-shares-of-natera-inc-ntra-2026-03-20/", "date": "2026-03-20", "summary": "CIBC Private Wealth Group LLC increased its stake in Natera, Inc. by 44.2% in the third quarter, acquiring 53,086 shares to hold a total of 173,088 shares valued at approximately $27.86 million. Natera reported better-than-expected quarterly earnings and revenue, though it remains unprofitable. The stock currently has a \"Moderate Buy\" consensus rating from analysts with an average target price of $253.47.", "sentiment_score": 0.035121, "sentiment_label": "Neutral", "relevance_score": 0.303566, "sentiment": { "label": "positive", "score": 0.66, "confidence": 0.66 } }, { "source": "alpha_vantage", "title": "Groupama Asset Managment Has $12.42 Million Stock Holdings in Natera, Inc. $NTRA", "url": "https://www.marketbeat.com/instant-alerts/filing-groupama-asset-managment-has-1242-million-stock-holdings-in-natera-inc-ntra-2026-03-19/", "date": "2026-03-19", "summary": "Groupama Asset Management significantly reduced its stake in Natera, Inc. by 25.9%, selling 26,989 shares and now holding 77,184 shares valued at $12.42 million. This move occurred alongside substantial insider sales from Natera's CFO and CEO, totaling over $28 million. Despite these sales and unprofitability, Natera exceeded earnings and revenue estimates last quarter, and analysts currently maintain a \"Moderate Buy\" consensus for the stock.", "sentiment_score": 0.108257, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.361, "confidence": 0.36 } }, { "source": "alpha_vantage", "title": "Natera, Inc. (NTRA) reports preliminary Q4 revenue", "url": "https://www.msn.com/en-us/health/other/natera-inc-ntra-reports-preliminary-q4-revenue/ar-AA1VfrkV?ocid=BingNewsVerp&apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1", "date": "2026-03-18", "summary": "This article reports that Natera, Inc. (NTRA) has released its preliminary revenue figures for the fourth quarter. The specific financial details would be included in the full article.", "sentiment_score": 0.127636, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Jonathan Sheena files Rule 144 notice selling shares (NASDAQ: NTRA)", "url": "https://www.stocktitan.net/sec-filings/NTRA/144-natera-inc-sec-filing-84ed2b9376b2.html", "date": "2026-03-18", "summary": "Jonathan Sheena has filed a Rule 144 notice indicating proposed sales of common stock in Natera, Inc. (NASDAQ: NTRA). The filing details several disposition dates and share amounts, such as 3,163 shares on January 21, 2026, and 3,070 shares on March 2, 2026, with transactions handled by Charles Schwab & Co., Inc. An analyst noted this as a routine procedural disclosure for resale.", "sentiment_score": 0.026341, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "Faithward Advisors LLC Invests $3.52 Million in Natera, Inc. $NTRA", "url": "https://www.marketbeat.com/instant-alerts/filing-faithward-advisors-llc-invests-352-million-in-natera-inc-ntra-2026-03-18/", "date": "2026-03-18", "summary": "Faithward Advisors LLC acquired a new stake of 21,843 shares in Natera, Inc. (NASDAQ:NTRA) during the third quarter, valued at approximately $3.52 million. This investment comes amidst significant insider selling, with 318,344 shares worth about $74.09 million sold in the last three months, though Natera recently beat earnings estimates. The company holds a \"Moderate Buy\" consensus rating from analysts with an average target price of $253.47.", "sentiment_score": 0.341381, "sentiment_label": "Somewhat-Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Livforsakringsbolaget Skandia Omsesidigt Buys 17,100 Shares of Natera, Inc. $NTRA", "url": "https://www.marketbeat.com/instant-alerts/filing-livforsakringsbolaget-skandia-omsesidigt-buys-17100-shares-of-natera-inc-ntra-2026-03-18/", "date": "2026-03-18", "summary": "Livforsakringsbolaget Skandia Omsesidigt significantly increased its stake in Natera, Inc. (NASDAQ:NTRA) by 213.9% in the third quarter, acquiring 17,100 additional shares to hold a total of 25,095 shares valued at $4.04 million. This move comes as Natera reported a strong quarterly beat, with EPS of $0.35 against an estimated -$0.46 and revenues of $665.5 million versus $600.7 million. Despite recent insider selling totaling $74.09 million, analysts maintain a \"Moderate Buy\" rating with an aver", "sentiment_score": 0.307704, "sentiment_label": "Somewhat-Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "Natera (NTRA) director sells 122 shares under 10b5-1 trading plan", "url": "https://www.stocktitan.net/sec-filings/NTRA/form-4-natera-inc-insider-trading-activity-951529ddbdf6.html", "date": "2026-03-18", "summary": "A Natera, Inc. director, Rowan E. Chapman, sold 122 shares of common stock at $191.38 per share on March 13, 2026, as part of a pre-arranged Rule 10b5-1 trading plan. This transaction, representing a small portion of his holdings, leaves Chapman with 5,752 direct shares. The filing of this Form 4 indicates a neutral impact with a negative sentiment.", "sentiment_score": -0.109113, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "Insider Selling: Natera (NASDAQ:NTRA) Director Sells 122 Shares of Stock", "url": "https://www.marketbeat.com/instant-alerts/insider-selling-natera-nasdaqntra-director-sells-122-shares-of-stock-2026-03-17/", "date": "2026-03-18", "summary": "Natera (NASDAQ:NTRA) Director Rowan Chapman sold 122 shares of the company's stock on March 13th, valued at $23,348.36, decreasing his stake by 2.08%. Despite recent sales, Natera exceeded earnings expectations with EPS of $0.35 and revenue of $665.5M, holding a consensus \"Moderate Buy\" rating among analysts with a price target of $253.47. The company specializes in genetic testing technologies for reproductive health, oncology, and organ transplantation.", "sentiment_score": 0.118446, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "Natera director Chapman sells $23348 in shares", "url": "https://www.investing.com/news/insider-trading-news/natera-director-chapman-sells-23348-in-shares-93CH-4567331", "date": "2026-03-18", "summary": "Rowan E. Chapman, a director at Natera, Inc. (NASDAQ:NTRA), sold 122 shares of the company's common stock for $23,348 on March 13, 2026. This transaction was part of a Rule 10b5-1 trading plan and leaves Chapman with 5752 shares. The company has recently seen positive news regarding its Signatera assay and launched a new whole-genome sequencing test, while analysts have maintained favorable ratings.", "sentiment_score": 0.226802, "sentiment_label": "Somewhat-Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "Natera (NTRA) chair Rabinowitz exercises options and sells 200,000 shares", "url": "https://www.stocktitan.net/sec-filings/NTRA/form-4-natera-inc-insider-trading-activity-75a54712ba4c.html", "date": "2026-03-17", "summary": "Natera's executive chairman, Matthew Rabinowitz, exercised stock options for 200,000 shares at $9.59 per share and subsequently sold all 200,000 shares in open-market transactions. The sales occurred at weighted average prices between approximately $186 and $198 per share, under a pre-arranged Rule 10b5-1 trading plan adopted in December 2025. Following these transactions, Rabinowitz directly holds 2,310,772 shares of Natera common stock, with an additional 5,000 shares held indirectly by his sp", "sentiment_score": 0.007903, "sentiment_label": "Neutral", "relevance_score": 0.314957, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "Holocene Advisors LP Decreases Stock Holdings in Natera, Inc. $NTRA", "url": "https://www.marketbeat.com/instant-alerts/filing-holocene-advisors-lp-decreases-stock-holdings-in-natera-inc-ntra-2026-03-17/", "date": "2026-03-17", "summary": "Holocene Advisors LP significantly reduced its stake in Natera, Inc. (NASDAQ:NTRA) by 43.8% in the third quarter, selling over 250,000 shares. Despite this, other institutional investors like JPMorgan Chase & Co., Norges Bank, and Vanguard Group Inc. increased their positions, indicating mixed institutional sentiment. The article also highlights recent insider stock sales by Natera's CFO and CEO, totaling over $28 million.", "sentiment_score": 0.007328, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Assessing Natera (NTRA) Valuation After New Signatera Data And Zenith Genomics Launch", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntra/natera/news/assessing-natera-ntra-valuation-after-new-signatera-data-and", "date": "2026-03-17", "summary": "Natera's stock is under recent scrutiny following the release of new peer-reviewed studies on its Signatera cancer assay and the commercial launch of Zenith genomics. Despite a recent share price jump, the stock has shown fading near-term momentum compared to its stronger one and three-year returns. While some models suggest Natera is undervalued significantly, its price-to-sales ratio indicates higher market expectations.", "sentiment_score": 0.337135, "sentiment_label": "Somewhat-Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Boothbay Fund Management LLC Increases Position in Natera, Inc. $NTRA", "url": "https://www.marketbeat.com/instant-alerts/filing-boothbay-fund-management-llc-increases-position-in-natera-inc-ntra-2026-03-17/", "date": "2026-03-17", "summary": "Boothbay Fund Management LLC significantly increased its stake in Natera, Inc. by 847.3% in the third quarter, now holding 17,497 shares valued at $2.82 million. Despite institutional ownership being high at 99.90%, insiders sold a notable amount of shares. Natera recently exceeded earnings expectations, reporting $0.35 EPS against a -$0.46 consensus, with a \"Moderate Buy\" analyst rating and a target of $253.47.", "sentiment_score": 0.402594, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Farallon Capital Management LLC Sells 568,357 Shares of Natera, Inc. $NTRA", "url": "https://www.marketbeat.com/instant-alerts/filing-farallon-capital-management-llc-sells-568357-shares-of-natera-inc-ntra-2026-03-16/", "date": "2026-03-16", "summary": "Farallon Capital Management LLC significantly reduced its stake in Natera, Inc. by 11.8% in the third quarter, selling 568,357 shares. Despite this reduction, Natera remains Farallon's fifth-largest holding, comprising 2.8% of its portfolio. Other institutional investors have also adjusted their positions, while analysts provide a range of ratings from \"Strong Buy\" to \"Sell\" with an average target price of $253.47.", "sentiment_score": -0.28739, "sentiment_label": "Somewhat-Bearish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "Fred Alger Management LLC Buys 41,303 Shares of Natera, Inc. $NTRA", "url": "https://www.marketbeat.com/instant-alerts/filing-fred-alger-management-llc-buys-41303-shares-of-natera-inc-ntra-2026-03-16/", "date": "2026-03-16", "summary": "Fred Alger Management LLC increased its stake in Natera, Inc. by 1.7% in Q3, purchasing 41,303 shares to hold a total of 2,451,779 shares valued at approximately $394.66 million. Natera reported strong quarterly earnings, beating revenue and EPS estimates, but remains unprofitable for the year with analysts forecasting a negative EPS of -1.49 for the current year. Despite insider selling, institutional ownership is high, and analysts have a \"Moderate Buy\" consensus with an average price target o", "sentiment_score": 0.207627, "sentiment_label": "Somewhat-Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "Cancer DNA test ties anal and rectal tumors to relapse odds", "url": "https://www.stocktitan.net/news/NTRA/two-publications-highlight-clinical-utility-of-signatera-tm-in-anal-o5zy4pwaob0p.html", "date": "2026-03-16", "summary": "Natera, Inc. announced new peer-reviewed publications showcasing the clinical utility of its personalized, tumor-informed circulating tumor DNA (ctDNA) assay, Signatera, in identifying relapse risk for anal and rectal cancers. The studies indicate that Signatera can help identify high-risk patients, inform non-operative management strategies, and precede clinical recurrence, potentially leading to more individualized surveillance and treatment decisions.", "sentiment_score": 0.046073, "sentiment_label": "Neutral", "relevance_score": 0.301083, "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "alpha_vantage", "title": "Coatue Management LLC Takes Position in Natera, Inc. $NTRA", "url": "https://www.marketbeat.com/instant-alerts/filing-coatue-management-llc-takes-position-in-natera-inc-ntra-2026-03-15/", "date": "2026-03-15", "summary": "Coatue Management LLC has acquired a new stake in Natera, Inc. (NASDAQ:NTRA), purchasing 170,326 shares valued at approximately $27.4 million during the third quarter. Institutional investors now own 99.90% of the company's stock, while top insiders recently sold shares totaling about $74.07 million. Despite beating earnings estimates and revenue expectations, Natera maintains a negative net margin and return on equity, with analysts holding a \"Moderate Buy\" consensus and an average price target", "sentiment_score": 0.138626, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Capital Impact Advisors LLC Boosts Stock Position in Natera, Inc. $NTRA", "url": "https://www.marketbeat.com/instant-alerts/filing-capital-impact-advisors-llc-boosts-stock-position-in-natera-inc-ntra-2026-03-15/", "date": "2026-03-15", "summary": "Capital Impact Advisors LLC significantly increased its stake in Natera, Inc. by 33.2% in Q3, now owning 65,059 shares valued at $10.47 million. Despite recent heavy insider selling totaling over $74 million, Natera reported strong Q3 earnings, beating analyst estimates, and holds a consensus \"Moderate Buy\" rating with an average target price of $253.47. The stock performed well, but analysts predict a negative EPS for the current fiscal year.", "sentiment_score": 0.133159, "sentiment_label": "Neutral", "relevance_score": 0.957927, "sentiment": { "label": "positive", "score": 0.318, "confidence": 0.32 } }, { "source": "alpha_vantage", "title": "Aquatic Capital Management LLC Increases Position in Natera, Inc. $NTRA", "url": "https://www.marketbeat.com/instant-alerts/filing-aquatic-capital-management-llc-increases-position-in-natera-inc-ntra-2026-03-15/", "date": "2026-03-15", "summary": "Aquatic Capital Management LLC significantly increased its stake in Natera, Inc. (NASDAQ:NTRA) by 210.5% in the third quarter of 2025, now owning 133,618 shares valued at $21.5 million. This increase comes despite recent insider selling, with CEO Steven Chapman and Solomon Moshkevich reducing their positions. Natera reported strong Q4 results, surpassing earnings and revenue expectations, and analysts generally maintain a \"Moderate Buy\" rating with a consensus target price of $253.47.", "sentiment_score": 0.394095, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "[144] Natera, Inc. SEC Filing", "url": "https://www.stocktitan.net/sec-filings/NTRA/144-natera-inc-sec-filing-621d17d8e324.html", "date": "2026-03-14", "summary": "This article details a Form 144 SEC filing by Natera, Inc. (NTRA) on March 13, 2026. The filing indicates a proposed sale of 122 shares with an aggregate market value of $23,348.36, acquired as restricted stock on January 26, 2025. The transaction involves Morgan Stanley Smith Barney LLC as the broker and will occur on NASDAQ.", "sentiment_score": 0.047755, "sentiment_label": "Neutral", "relevance_score": 0.336016, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "GeneDx stock falls as Natera launches competing rare disease test", "url": "https://www.investing.com/news/stock-market-news/genedx-stock-falls-as-natera-launches-competing-rare-disease-test-93CH-4557824", "date": "2026-03-12", "summary": "GeneDx Holdings Corp (NASDAQ:WGS) shares dropped by 7.8% after Natera Inc (NASDAQ:NTRA) commercially launched its Zenith genomics whole genome sequencing assay for rare disease diagnosis. The new test, developed by MyOme in partnership with Natera, aims to improve the detection of rare genetic conditions using long-read sequencing. Additionally, insider selling by GeneDx's CEO and CFO to cover tax obligations from restricted stock unit vesting contributed to the stock's pressure.", "sentiment_score": 0.407903, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Natera Announces Commercial Launch of Zenith™ Genomics for Rare Disease Diagnosis", "url": "https://www.businesswire.com/news/home/20260312908723/en/Natera-Announces-Commercial-Launch-of-Zenith-Genomics-for-Rare-Disease-Diagnosis", "date": "2026-03-12", "summary": "Natera, Inc. announced the commercial launch of Zenith™ genomics, a new whole-genome sequencing assay designed to significantly improve the detection and diagnosis of rare diseases. This solution aims to shorten diagnostic journeys for millions of Americans affected by rare genetic conditions, addressing a substantial economic and societal burden. Developed in partnership with MyOme, Zenith genomics offers enhanced resolution and comprehensive analysis to guide targeted therapies and clinical ma", "sentiment_score": 0.456047, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "New genome test from Natera and MyOme targets 5-year rare disease delays", "url": "https://www.stocktitan.net/news/NTRA/my-ome-debuts-zenith-tm-portfolio-with-natera-and-launches-long-read-8vr2ni613gga.html", "date": "2026-03-12", "summary": "MyOme and Natera (NASDAQ: NTRA) have launched the Zenith™ portfolio, a premium exome and genome testing solution integrating MyOme's long-read methylation analysis with Natera's clinical network. This new offering aims to address the average five-year diagnostic delay for rare disease patients by moving beyond traditional DNA sequencing. The methylation analysis will be automatically added to eligible rare disease orders starting early Q2 2026, initially for targeted confirmation of select condi", "sentiment_score": 0.442559, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Natera, Inc. $NTRA Shares Sold by Swiss National Bank", "url": "https://www.marketbeat.com/instant-alerts/filing-natera-inc-ntra-shares-sold-by-swiss-national-bank-2026-03-12/", "date": "2026-03-12", "summary": "Swiss National Bank recently trimmed its stake in Natera, Inc. (NTRA) by 3.8% in the third quarter, selling 14,900 shares, though still holding 0.27% of the company valued at $60.19 million. Concurrently, insider selling by CEO Steven Leonard Chapman and other insiders amounted to significant share disposals, while institutional investors collectively own 99.90% of the stock. Despite this, Natera reported strong earnings, beating analyst expectations, and maintains a consensus \"Moderate Buy\" rat", "sentiment_score": 0.127366, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "Natera, Inc. $NTRA Shares Bought by Franklin Resources Inc.", "url": "https://www.marketbeat.com/instant-alerts/filing-natera-inc-ntra-shares-bought-by-franklin-resources-inc-2026-03-12/", "date": "2026-03-12", "summary": "Franklin Resources Inc. has increased its stake in Natera, Inc. (NASDAQ:NTRA) by 37.5%, now owning 2,665,013 shares valued at approximately $428.99 million. This comes as Natera reported better-than-expected earnings and revenue last quarter, despite significant insider selling totaling over $86 million. Institutional investors collectively hold about 99.90% of the company's stock.", "sentiment_score": 0.422649, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "Capital Fund Management S.A. Buys 41,307 Shares of Natera, Inc. $NTRA", "url": "https://www.marketbeat.com/instant-alerts/filing-capital-fund-management-sa-buys-41307-shares-of-natera-inc-ntra-2026-03-12/", "date": "2026-03-12", "summary": "Capital Fund Management S.A. significantly increased its stake in Natera, Inc. by 59.4% in the third quarter, acquiring an additional 41,307 shares to hold a total of 110,870 shares valued at approximately $17.85 million. This comes despite Natera's recent earnings beat ($0.35 EPS vs. -$0.46 consensus) and robust revenue growth ($665.5 million vs. $600.7 million estimate), as the company remains unprofitable with a negative net margin and ROE. Notably, Natera has seen net selling from company in", "sentiment_score": 0.282152, "sentiment_label": "Somewhat-Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "Natera (NASDAQ: NTRA) president awarded RSUs, sells shares for tax", "url": "https://www.stocktitan.net/sec-filings/NTRA/form-4-natera-inc-insider-trading-activity-722ad38ac134.html", "date": "2026-03-12", "summary": "John Fesko, President and Chief Business Officer of Natera, Inc. (NASDAQ: NTRA), was granted 1,774 fully vested Restricted Stock Units (RSUs). Subsequently, he sold 707 shares of Natera common stock at $204.1327 per share to cover tax withholding obligations related to the RSU vesting, a transaction consistent with Rule 10b5-1(c) conditions. After these transactions, Fesko directly held 189,199 shares of the company's common stock.", "sentiment_score": 0.08285, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.599, "confidence": 0.6 } }, { "source": "alpha_vantage", "title": "Natera (NTRA) co-founder reports RSU grant and small tax-driven share sale", "url": "https://www.stocktitan.net/sec-filings/NTRA/form-4-natera-inc-insider-trading-activity-2bc4ce9b035e.html", "date": "2026-03-12", "summary": "Sheena Jonathan, co-founder and director at Natera, Inc. (NTRA), reported the grant of 258 fully vested Restricted Stock Units (RSUs) on March 9, 2026. Following this, on March 10, 2026, she sold 127 shares of Common Stock at an average price of $204.1327 per share. This sale was conducted to satisfy tax withholding obligations associated with the RSU vesting and was executed under a Rule 10b5-1 plan.", "sentiment_score": 0.041207, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.572, "confidence": 0.57 } }, { "source": "alpha_vantage", "title": "Natera CFO Brophy sells $160k in NTRA stock", "url": "https://www.investing.com/news/insider-trading-news/natera-cfo-brophy-sells-160k-in-ntra-stock-93CH-4556022", "date": "2026-03-12", "summary": "Michael Burkes Brophy, CFO of Natera Inc. (NASDAQ:NTRA), sold 785 shares of company stock for approximately $160,244 on March 10, 2026, after the stock delivered a 36% return over the past year. Earlier, on March 9, 2026, Brophy acquired 1,968 fully-vested Restricted Stock Units. Despite the sale, Natera recently reported strong Q4 2025 revenues, surpassing expectations, and received varied price targets from analysts, with Canaccord Genuity reiterating a Buy rating and Morgan Stanley maintainin", "sentiment_score": 0.108941, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Natera CFO Brophy sells $160k in NTRA stock", "url": "https://m.investing.com/news/insider-trading-news/natera-cfo-brophy-sells-160k-in-ntra-stock-93CH-4556022?ampMode=1", "date": "2026-03-12", "summary": "Natera Inc.'s CFO, Michael Burkes Brophy, sold 785 shares of NTRA stock for approximately $160,244 on March 10, 2026, though the current stock price is below his transaction price. This follows his acquisition of 1,968 fully-vested Restricted Stock Units on March 9, 2026, bringing his total direct ownership to 63,354 shares. The company recently reported strong Q4 2025 revenues, surpassing expectations, and received varied analyst ratings, including a reiterated Buy from Canaccord Genuity and an", "sentiment_score": 0.132624, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Michael Burkes Brophy Sells 785 Shares of Natera (NASDAQ:NTRA) Stock", "url": "https://www.marketbeat.com/instant-alerts/michael-burkes-brophy-sells-785-shares-of-natera-nasdaqntra-stock-2026-03-11/", "date": "2026-03-12", "summary": "Michael Burkes Brophy, CFO of Natera (NASDAQ:NTRA), sold 785 shares of the company's stock for $160,242.05 on March 10th, reducing his stake by 1.22% to 63,354 shares. This transaction is part of a series of insider sales by Brophy earlier in the year, totaling millions of dollars. Despite the insider selling, Natera recently beat Q4 expectations with $0.35 EPS and $665.5 million in revenue, and analysts maintain a \"Moderate Buy\" rating with a target price of $253.47.", "sentiment_score": -0.131547, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "Natera (NASDAQ:NTRA) Insider John Fesko Sells 707 Shares of Stock", "url": "https://www.marketbeat.com/instant-alerts/natera-nasdaqntra-insider-john-fesko-sells-707-shares-of-stock-2026-03-11/", "date": "2026-03-12", "summary": "Natera insider John Fesko sold 707 shares of the company's stock on March 10th for $204.13 per share, reducing his stake by 0.37%. This follows a pattern of recent sales by Fesko, including a significant transaction in January. The company recently reported strong earnings, exceeding analyst expectations, and maintains a \"Moderate Buy\" consensus rating among analysts.", "sentiment_score": -0.144281, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "Insider Selling: Natera (NASDAQ:NTRA) CEO Sells 5,623 Shares of Stock", "url": "https://www.marketbeat.com/instant-alerts/insider-selling-natera-nasdaqntra-ceo-sells-5623-shares-of-stock-2026-03-11/", "date": "2026-03-12", "summary": "Natera (NASDAQ: NTRA) CEO Steven Leonard Chapman sold 5,623 shares of the company's stock for over $1.14 million on March 10th, reducing his stake by 3.47%. This sale is part of a larger pattern of significant insider sales observed since January. Despite recent positive quarterly earnings, the company still faces negative margins and a negative yearly EPS outlook, though analysts maintain a \"Moderate Buy\" rating with an average target price of $253.47.", "sentiment_score": -0.287, "sentiment_label": "Somewhat-Bearish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "pubmed", "pmid": "41912809", "title": "Quemliclustat and chemotherapy with or without zimberelimab in metastatic pancreatic adenocarcinoma: a randomized phase 1 trial.", "authors": "Wainberg ZA et al.", "journal": "Nature medicine", "date": "2026 Mar 3", "url": "https://pubmed.ncbi.nlm.nih.gov/41912809/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41904847", "title": "Evaluating the safety and efficacy of chemotherapy in patients with relapsed small cell lung cancer combined with allopurinol and MycoPhenolate (CLAMP).", "authors": "Knapp B et al.", "journal": "Lung cancer (Amsterdam, Netherlands)", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41904847/", "sentiment": { "label": "negative", "score": -0.382, "confidence": 0.38 } }, { "source": "pubmed", "pmid": "41903855", "title": "Organ-specific differences in the epidemiology of cytomegalovirus infections in high-risk (CMV D+R-) solid organ transplant recipients with prolonged follow-up: a ten-year experience.", "authors": "Heldman MR et al.", "journal": "American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41903855/", "sentiment": { "label": "positive", "score": 0.153, "confidence": 0.15 } }, { "source": "pubmed", "pmid": "41903539", "title": "Advancing precision health discovery in a genetically diverse health system.", "authors": "Haas R et al.", "journal": "Cell", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41903539/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41896510", "title": "ASO Author Reflections: New Insights for Personalized HIPEC Strategies in Colorectal Cancer Peritoneal Metastases.", "authors": "Gupta P et al.", "journal": "Annals of surgical oncology", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41896510/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41895280", "title": "Cancer type-specific variation in patterns of driver alterations across 50,000 tumors.", "authors": "Bandlamudi C et al.", "journal": "Cancer cell", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41895280/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41893841", "title": "Discontinuation of RAS Inhibition After an Acute Decline in Estimated Glomerular Filtration Rate.", "authors": "Ku E et al.", "journal": "JAMA network open", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41893841/", "sentiment": { "label": "negative", "score": -0.561, "confidence": 0.56 } }, { "source": "pubmed", "pmid": "41891361", "title": "Disparities in Genetic Testing: Evaluation of Reproductive Carrier Screening in the United States.", "authors": "Parmar S et al.", "journal": "Genetics in medicine : official journal of the American College of Medical Genetics", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41891361/", "sentiment": { "label": "positive", "score": 0.421, "confidence": 0.42 } }, { "source": "pubmed", "pmid": "41883872", "title": "Molecular complete response to the RIN protocol (regorafenib, ipilimumab, and nivolumab) in a patient with advanced recurrent metastatic mismatch repair proficient/microsatellite stable (pMMR/MSS) rectal cancer.", "authors": "Qadri F et al.", "journal": "Therapeutic advances in medical oncology", "date": "2026-03-31", "url": "https://pubmed.ncbi.nlm.nih.gov/41883872/", "sentiment": { "label": "negative", "score": -0.296, "confidence": 0.3 } }, { "source": "pubmed", "pmid": "41882705", "title": "Expression of complement pathway genes is associated with progression of idiopathic pulmonary fibrosis.", "authors": "Swaminathan AC et al.", "journal": "Respiratory research", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41882705/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41880691", "title": "CHIO3: CHemotherapy combined with immune checkpoint inhibitor for operable stage IIIA/B (N2) Non-Small cell lung cancer (AFT-46).", "authors": "Martin LW et al.", "journal": "Lung cancer (Amsterdam, Netherlands)", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41880691/", "sentiment": { "label": "negative", "score": -0.542, "confidence": 0.54 } }, { "source": "pubmed", "pmid": "41875915", "title": "Proton therapy for oropharyngeal cancer: survival, toxicity, and functional outcomes.", "authors": "Vargas CE", "journal": "Lancet (London, England)", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41875915/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41874669", "title": "Risk factors for immune checkpoint inhibitor colitis: a retrospective multi-center cohort study using electronic health records.", "authors": "Chu DHT et al.", "journal": "Cancer immunology, immunotherapy : CII", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41874669/", "sentiment": { "label": "negative", "score": -0.052, "confidence": 0.05 } }, { "source": "pubmed", "pmid": "41874648", "title": "Real-world effectiveness of avelumab, pembrolizumab, and enfortumab vedotin in patients with advanced urothelial carcinoma with squamous differentiation (ARON-2EV).", "authors": "Mollica V et al.", "journal": "Cancer immunology, immunotherapy : CII", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41874648/", "sentiment": { "label": "positive", "score": 0.25, "confidence": 0.25 } }, { "source": "pubmed", "pmid": "41873434", "title": "Advanced artificial intelligence vs simpler models for 1-year death prediction among patients receiving hemodialysis.", "authors": "K K et al.", "journal": "JAMIA open", "date": "2026-03-31", "url": "https://pubmed.ncbi.nlm.nih.gov/41873434/", "sentiment": { "label": "positive", "score": 0.052, "confidence": 0.05 } }, { "source": "pubmed", "pmid": "41872254", "title": "Monitoring treatment response using an ultra-sensitive ctDNA assay in advanced esophagogastric cancer patients.", "authors": "Nixon AB et al.", "journal": "Scientific reports", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41872254/", "sentiment": { "label": "negative", "score": -0.527, "confidence": 0.53 } }, { "source": "pubmed", "pmid": "41867849", "title": "Senescence-directed nanotherapy ameliorates fibrosis and overcomes immune exclusion in cancer.", "authors": "Hinterleitner C et al.", "journal": "bioRxiv : the preprint server for biology", "date": "2026 Mar 4", "url": "https://pubmed.ncbi.nlm.nih.gov/41867849/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41864057", "title": "Impact of pathologic response and individual prognosis after neoadjuvant treatment in patients with early HER2+ and triple-negative breast cancer.", "authors": "Corti C et al.", "journal": "Breast (Edinburgh, Scotland)", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41864057/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41862950", "title": "Long-term efficacy and safety of pegunigalsidase alfa administered every 4 weeks in adults with Fabry disease: results from up to 5 years of the BRIGHT F51 phase III, open-label extension study.", "authors": "Holida M et al.", "journal": "Orphanet journal of rare diseases", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41862950/", "sentiment": { "label": "positive", "score": 0.753, "confidence": 0.75 } }, { "source": "pubmed", "pmid": "41862439", "title": "Efficacy of stem cell boost (SCB) for chimeric antigen receptor-T cell therapy (CAR-T)-related hematologic toxicity in patients with relapsed/refractory multiple myeloma (RRMM)-real world experience from the US multiple myeloma immunotherapy consortium.", "authors": "Varga C et al.", "journal": "Blood cancer journal", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41862439/", "sentiment": { "label": "positive", "score": 0.402, "confidence": 0.4 } }, { "source": "pubmed", "pmid": "41861751", "title": "Sacituzumab govitecan in patients with metastatic breast cancer: pooled safety analysis of data from patients in North America, Europe, and Asia.", "authors": "Rugo HS et al.", "journal": "ESMO open", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41861751/", "sentiment": { "label": "negative", "score": -0.382, "confidence": 0.38 } }, { "source": "pubmed", "pmid": "41860673", "title": "Photochemical transformation of paracetamol sensitized by humic acid: pH-dependent pathways and mechanisms.", "authors": "Barrera A et al.", "journal": "Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41860673/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41860506", "title": "Physician-Directed Patient Self-Management Using an Implantable IVC Congestion Sensor: Insights From FUTURE-HFII.", "authors": "Uriel N et al.", "journal": "JACC. Heart failure", "date": "2026 Mar 3", "url": "https://pubmed.ncbi.nlm.nih.gov/41860506/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41854411", "title": "Use of ctDNA in Older Women with ER+ Breast Cancer to Facilitate Surgical De-escalation: A Prospective, Hybrid-Decentralized Trial with Correlative Studies.", "authors": "Carleton N et al.", "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41854411/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41851467", "title": "Thymic health and immunotherapy outcomes in patients with cancer.", "authors": "Bernatz S et al.", "journal": "Nature", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41851467/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41851087", "title": "The combination of a cancer vaccine, pembrolizumab, and stereotactic body radiation in patients with locally advanced pancreatic cancer: a single-arm, phase II study.", "authors": "Lee V et al.", "journal": "Nature communications", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41851087/", "sentiment": { "label": "negative", "score": -0.832, "confidence": 0.83 } }, { "source": "pubmed", "pmid": "41850040", "title": "Phase III trial of infigratinib versus gemcitabine/cisplatin in adults with advanced cholangiocarcinoma with FGFR2 gene fusion or rearrangement: results and reflections on early termination of PROOF 301.", "authors": "Abou-Alfa GK et al.", "journal": "ESMO open", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41850040/", "sentiment": { "label": "positive", "score": 0.25, "confidence": 0.25 } }, { "source": "pubmed", "pmid": "41848733", "title": "An AI Approach to Differentiating Lung Squamous Cell Carcinoma From Metastases of Other Origins.", "authors": "Evans MG et al.", "journal": "JAMA network open", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41848733/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41844862", "title": "Decentralized clinical trials in cardiovascular disease : A primer for clinical trialists.", "authors": "Baudry G et al.", "journal": "Nature cardiovascular research", "date": "2026-03-31", "url": "https://pubmed.ncbi.nlm.nih.gov/41844862/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41843836", "title": "Prevalence of High-Risk Human Papillomavirus and Associated Risk Factors Among Individuals With Head and Neck Cancer in a National Referral Center in Tanzania.", "authors": "Nkya A et al.", "journal": "JCO global oncology", "date": "2026-03-31", "url": "https://pubmed.ncbi.nlm.nih.gov/41843836/", "sentiment": { "label": "negative", "score": -0.758, "confidence": 0.76 } }, { "source": "pubmed", "pmid": "41843049", "title": "Clinically Meaningful, Patient-Centered Endpoints for Real-World Evidence Generation in Breast Cancer: Perspectives from the Multidisciplinary TRIUMPH Initiative.", "authors": "Khozin S et al.", "journal": "Advances in therapy", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41843049/", "sentiment": { "label": "positive", "score": 0.186, "confidence": 0.19 } }, { "source": "pubmed", "pmid": "41840743", "title": "Microsimulation model to identify suboptimal recurrence detection in patients with colorectal cancer following the current standard of care.", "authors": "Samur S et al.", "journal": "BMJ open", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41840743/", "sentiment": { "label": "negative", "score": -0.296, "confidence": 0.3 } }, { "source": "pubmed", "pmid": "41838361", "title": "Real-World Outcomes for Patients with Clinically Node-Positive Melanoma Undergoing Neoadjuvant Immunotherapy and Nodal Dissection.", "authors": "Herb J et al.", "journal": "Annals of surgical oncology", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41838361/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41837795", "title": "AI-assisted Qualitative Research on Kidney Failure Treatment Decisions.", "authors": "Bicki A et al.", "journal": "Transplantation", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41837795/", "sentiment": { "label": "negative", "score": -0.511, "confidence": 0.51 } }, { "source": "pubmed", "pmid": "41833593", "title": "Comparing DSA-negative and DSA-positive antibody-mediated rejection in heart transplants: results from the Trifecta-Heart study.", "authors": "Madill-Thomsen KS et al.", "journal": "The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41833593/", "sentiment": { "label": "positive", "score": 0.178, "confidence": 0.18 } }, { "source": "pubmed", "pmid": "41830435", "title": "Impact of everolimus-related interstitial lung disease on subsequent treatment in patients with metastatic breast cancer.", "authors": "Kiyohara H et al.", "journal": "The oncologist", "date": "2026 Mar 9", "url": "https://pubmed.ncbi.nlm.nih.gov/41830435/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41830429", "title": "Telemedicine as a gateway to early-phase oncology trials: lessons from 14 000 patients and future directions for global access and equity.", "authors": "Torrado C et al.", "journal": "The oncologist", "date": "2026 Mar 9", "url": "https://pubmed.ncbi.nlm.nih.gov/41830429/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41826432", "title": "Quantitative HER2 tissue and plasma profiling predicts the activity of trastuzumab deruxtecan for breast cancer.", "authors": "Tarantino P et al.", "journal": "NPJ precision oncology", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41826432/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41818856", "title": "Supplementation of organelle-specific antioxidants during in vitro oocyte maturation enhances embryo development and pregnancy outcomes in bovine.", "authors": "Gebremedhn S et al.", "journal": "Theriogenology", "date": "2026 Mar 5", "url": "https://pubmed.ncbi.nlm.nih.gov/41818856/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41817930", "title": "ASO Visual Abstract: Surgical Outcomes After Neoadjuvant Pembrolizumab Plus Chemotherapy for Triple-Negative Breast Cancer-Results from the Randomized, Placebo-Controlled Phase 3 KEYNOTE-522 Study.", "authors": "Kuemmel S et al.", "journal": "Annals of surgical oncology", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41817930/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41811315", "title": "Precision Diagnosis in APOL1 Kidney Disease With the p.N264K M1 Protective Variant.", "authors": "Martinelli E et al.", "journal": "JAMA network open", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41811315/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41807638", "title": "Advances in the management of metastatic gastric cancer: current strategies and emerging therapeutics.", "authors": "Choo J et al.", "journal": "Nature reviews. Clinical oncology", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41807638/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41804750", "title": "Multi-omic profiling defines three distinct molecular subtypes of urothelial carcinoma with implications for precision therapy.", "authors": "van Creij NCH et al.", "journal": "Clinical and translational medicine", "date": "2026-03-31", "url": "https://pubmed.ncbi.nlm.nih.gov/41804750/", "sentiment": { "label": "negative", "score": -0.2, "confidence": 0.2 } }, { "source": "pubmed", "pmid": "41793510", "title": "A phase II study of atezolizumab in combination with stereotactic radiation for patients with triple-negative breast cancer and brain metastasis.", "authors": "Giordano A et al.", "journal": "Breast cancer research and treatment", "date": "2026 Mar 7", "url": "https://pubmed.ncbi.nlm.nih.gov/41793510/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41791849", "title": "Novel insights into autoimmune gastritis: clinical profile and gastric neoplastic risk from an international multicentre study.", "authors": "Lenti MV et al.", "journal": "Gut", "date": "2026 Mar 6", "url": "https://pubmed.ncbi.nlm.nih.gov/41791849/", "sentiment": { "label": "positive", "score": 0.052, "confidence": 0.05 } }, { "source": "pubmed", "pmid": "41791237", "title": "\"A lot of the times, patients really don't know what questions to ask:\" Communication perspectives of Black patients with advanced lung cancer.", "authors": "AuBuchon KE et al.", "journal": "Patient education and counseling", "date": "2026 Mar 3", "url": "https://pubmed.ncbi.nlm.nih.gov/41791237/", "sentiment": { "label": "negative", "score": -0.527, "confidence": 0.53 } }, { "source": "pubmed", "pmid": "41790338", "title": "Clinical development of molecular residual disease (MRD) and multi-cancer early detection (MCED) using liquid biopsy multiomics with artificial intelligence (AI).", "authors": "Shibuki T et al.", "journal": "International journal of clinical oncology", "date": "2026 Mar 6", "url": "https://pubmed.ncbi.nlm.nih.gov/41790338/", "sentiment": { "label": "positive", "score": 0.477, "confidence": 0.48 } }, { "source": "pubmed", "pmid": "41785668", "title": "Imlunestrant plus abemaciclib versus fulvestrant plus abemaciclib in ER-positive, HER2-negative advanced breast cancer: an indirect treatment comparison of three phase III trials.", "authors": "Jhaveri K et al.", "journal": "ESMO open", "date": "2026-03-31", "url": "https://pubmed.ncbi.nlm.nih.gov/41785668/", "sentiment": { "label": "negative", "score": -0.527, "confidence": 0.53 } }, { "source": "pubmed", "pmid": "41781623", "title": "Homologous recombination deficiency and hemizygosity drive resistance in breast cancer.", "authors": "Safonov A et al.", "journal": "Nature", "date": "2026 Mar 4", "url": "https://pubmed.ncbi.nlm.nih.gov/41781623/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41781620", "title": "A glucocorticoid-FAS axis controls immune evasion during metastatic seeding.", "authors": "Cassandras M et al.", "journal": "Nature", "date": "2026 Mar 4", "url": "https://pubmed.ncbi.nlm.nih.gov/41781620/", "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } } ] } }